CHARACTERISTICS OF DIAGNOSIS AND TREATMENT OF EXTRA-CRANIAL MALIGNANT GERM CELL TUMORS AT CHILDREN HOSPITAL 2
Main Article Content
Abstract
Background and aims: Germ cell tumors are a group of malignancies that originate in sex cells during development and migration. Tumors can originate from the gonadal tract such as testes, ovaries, or extra-gonadal such as intracranial, mediastinal, sacral, uterine, vaginal and account for 3.5% of all childhood cancers. under 15 years old. Treatment options for germ cell malignancies include surgery, chemotherapy, and radiation therapy, of which radiotherapy is used less and less often because of the long-term consequences of radiation exposure in children. This study aims to investigate the diagnostic and treatment characteristics of extracranial germ cell tumor treated at Children's Hospital 2. Methods: A prospective descriptive case series study in all pediatric patients were diagnosed with extracranial malignant germ cell tumors at the Department of Hematology Oncology, Children's Hospital 2 from January 1, 2011 to July 31, 2019. ata were entered using REDCap software and analyzed using SPSS 20.0 software. Results: We recorded 69 patients who met the sampling criteria in which malignant germ cell tumors in the genital tract accounted for 69.6%, yolk sac tumor accounted for 59.4%. Median age was 25 months old. The most common symptom of the disease was tumor detection (60.9%) followed by abdominal pain (15%). The average tumor size is 8.4cm, the largest size is ovarian tumor, the smallest is testicular tumor. The median values of AFP and β-HCG were 3,083.2 ng/mL and 60 IU/mL, respectively. The most common histopathological type is yolk sac tumor, accounting for 59.4%. There were 31.9% tumors stage I, 15.9% stage II, 31.9% stage III and 13% stage IV. There were 29% low-risk, 30.4% medium-risk and 30.4% high-risk tumors. The mean duration of treatment was 119.1 days. The treatment method is surgery combined with chemotherapy. The main chemotherapy regimen is JEB accounted for 92.8%, PEb regimen accounted for 7.2%. Conclusions: Malignant extracranial germ cell tumors in children are mainly gonadal tumors, the common histology is yolk sac tumor. Median age of detection was 25 months, the most common symptom onset was abdominal pain, 44% of tumors were detected at stage III-IV and 30.3% at high risk. The mean duration of treatment was 119.1 days. The main chemotherapy regimen is JEB accounted for 92.8%, PEb regimen accounted for 7.2%.
Article Details
Keywords
germ cell tumor, malignant germ cell tumor, extracranial germ cell tumor
References
2. G. Calaminus et al. (2020), "Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology", Cancers (Basel), 12, (3),
3. G. Cecchetto (2014), "Gonadal germ cell tumors in children and adolescents", J Indian Assoc Pediatr Surg, 19, (4), 189-194
4. S. Depani et al. (2019), "Results from the UK Children's Cancer and Leukaemia Group study of extracranial germ cell tumours in children and adolescents (GCIII)", Eur J Cancer, 118, 49-57
5. A. L. Frazier et al. (2015), "Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States", J Clin Oncol, 33, (2), 195-201
6. U. Gobel et al. (2013), "Testicular germ cell tumors in boys <10 years: results of the protocol MAHO 98 in respect to surgery and watch & wait strategy", Klin Padiatr, 225, (6), 296-302
7. G. A. Hale et al. (1999), "Late effects of treatment for germ cell tumors during childhood and adolescence", J Pediatr Hematol Oncol, 21, (2), 115-122
8. "International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group", (1997), J Clin Oncol, 15, (2), 594-603
9. A. E. Lawrence et al. (2020), "Understanding the Value of Tumor Markers in Pediatric Ovarian Neoplasms", J Pediatr Surg, 55, (1), 122-125